Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
The US Food and Drug Administration (FDA) has granted Fast Track designation for Carisma Therapeutics’ CT-0525 for the treatment of …
The US Food and Drug Administration (FDA) has granted Fast Track designation for Carisma Therapeutics’ CT-0525 for the treatment of …
The China National Medical Products Administration (NMPA) has granted marketing approval for Simcere Zaiming’s Enlituo for the treatment of metastatic …
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application (NDA) …
AstraZeneca has announced approval from the Japanese Pharmaceuticals and Medical Device Agency for Tagrisso (osimertinib) plus chemotherapy as a first-line treatment of …
Although the pharma industry's dealmaking activity in the last 12 months has yet to surpass the peak levels seen in …
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application (NDA) …
AstraZeneca has announced approval from the Japanese Pharmaceuticals and Medical Device Agency for Tagrisso (osimertinib) plus chemotherapy as a first-line treatment of …
Although the pharma industry's dealmaking activity in the last 12 months has yet to surpass the peak levels seen in …
After trialling a subscription-style system for procuring antimicrobial drugs, the UK’s National Health Service recently announced that it will formalise …
Medical packaging companies in pharmaceutical contract manufacturing: Introduction In the complex world of pharmaceuticals, the role of medical packaging companies is …
Pharma packaging solutions, design and companies: Introduction In the highly regulated and competitive pharmaceutical industry, the packaging is not merely a …
German biotechnology company Ethris has announced initial positive Phase I data demonstrating the safety of its lead intranasal mRNA candidate …
Merck KGaA (Merck) has discontinued the Phase III TrilynX trial evaluating xevinapant in patients with unresected locally advanced squamous cell …
Oncoinvent has received fast-track designation from the US Food and Drug Administration (FDA) for its therapy, Radspherin, to treat peritoneal …
Novavax has submitted a type II variation application with the European Medicines Agency (EMA) seeking approval for its updated JN.1 …